variables |
Univariate analysis |
Univariate analysis |
Multiple
linear regression |
Multiple linear regression |
|
r |
P |
β |
P |
AGE (years) |
0.177 |
0.031* |
|
|
WT (kg) |
0.183 |
0.025* |
|
|
Dose (mg/kg) |
0.112 |
0.172 |
|
|
BMI (kg/m2) |
0.05 |
0.548 |
|
|
BSA (m2) |
0.181 |
0.028* |
|
|
HGB (g/L) |
-0.29 |
<0.001* |
|
|
PLT (109/L) |
-0.283 |
<0.001* |
|
|
WBC (109/L) |
-0.184 |
0.025* |
|
|
NEU (109/L) |
-0.129 |
0.117 |
|
|
TBIL (μmol/L) |
0.311 |
<0.001* |
|
|
GGT (U/L) |
-0.089 |
0.281 |
|
|
ALT (U/L) |
0.051 |
0.54 |
|
|
AST (U/L) |
0.078 |
0.343 |
|
|
ALP (U/L) |
-0.006 |
0.939 |
|
|
ALB(g/L) |
-0.418 |
<0.001* |
-0.19 |
0.000** |
SCR (μmol/L) |
0.066 |
0.423 |
|
|
CYSC (mg/L) |
0.005 |
0.952 |
|
|
Ccr (mL/min) |
-0.02 |
0.565 |
|
|
Gender |
|
0.646 |
|
|
male |
|
|
|
|
famale |
|
|
|
|
Route of administration |
|
0.038* |
|
|
intravenous |
|
|
1.801 |
0.004** |
oral |
|
|
|
|
CYP2C19 genotype |
|
0.038* |
|
|
EM |
|
|
|
|
IM, PM |
|
|
|
|
Concomitant drugs |
|
|
|
|
PPIs |
|
0.004* |
|
|
yes |
|
|
1.985 |
0.004** |
no |
|
|
|
|
GLU |
|
0.084* |
|
|
yes |
|
|
-1.548 |
0.004** |
no |
|
|
|
|